Abstract
Purpose Per2, a core circadian clock gene, has tumor suppressor properties and is mutated or down regulated in human breast cancers. We have manipulated the expression of this gene in vitro and in vivo to more fully understand how the Per2 clock gene product affects cancer growth. Methods We used siRNA and shRNA to down regulate Per2 expression in vitro and in vivo and measured cancer cell proliferation, tumor growth rate and several molecular pathways relevant to cancer growth and their circadian organizations. All statistical tests were two-sided. Results Down regulation of functional Per2 gene expression increases Cyclin D and Cyclin E levels and doubles in vitro breast cancer cell proliferation (P < 0.05). Down regulation of Per2 also accelerates in vivo tumor growth and doubles the daily amplitude of the tumor growth rhythm (P < 0.05). Conclusions The clock gene Per2 exerts its tumor suppressor function in a circadian time dependent manner. Therefore, Per2 and perhaps other clock genes represent a new class of potential therapeutic targets whose manipulation will modulate cancer growth and cancer cell proliferation.
References
Cermakian N, Boivin DB (2003) A molecular perspective of human circadian rhythm disorders. Brain Res Brain Res Rev 42(3):204–220. doi:10.1016/S0165-0173(03)00171-1
Vansteensel MJ, Michel S, Meijer JH (2008) Organization of cell and tissue circadian pacemakers: a comparison among species. Brain Res Rev 58(1):18–47
Reppert SM, Weaver DR (2002) Coordination of circadian timing in mammals. Nature 418(6901):935–941. doi:10.1038/nature00965
Herzog ED (2007) Neurons and networks in daily rhythms. Nat Rev Neurosci 8(10):790–802. doi:10.1038/nrn2215
Liu AC et al (2007) Intercellular coupling confers robustness against mutations in the SCN circadian clock network. Cell 129(3):605–616. doi:10.1016/j.cell.2007.02.047
Kuhlman SJ, McMahon DG (2006) Encoding the ins and outs of circadian pacemaking. J Biol Rhythms 21(6):470–481. doi:10.1177/0748730406294316
Lee C et al (2001) Posttranslational mechanisms regulate the mammalian circadian clock. Cell 107(7):855–867. doi:10.1016/S0092-8674(01)00610-9
Ko CH, Takahashi JS (2006) Molecular components of the mammalian circadian clock. Hum Mol Genet 15(Spec No 2):R271–R277
Schibler U (2007) The daily timing of gene expression and physiology in mammals. Dialogues Clin Neurosci 9(3):257–272
Oishi K et al (2003) Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J Biol Chem 278(42):41519–41527. doi:10.1074/jbc.M304564200
Lowrey PL, Takahashi JS (2004) Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet 5:407–441. doi:10.1146/annurev.genom.5.061903.175925
Buchi K et al (1991) Circadian rhythm of cellular proliferation in the human rectal mucosa. Gastroenterology 101:410–415
Bjarnason GA et al (2001) Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol 158(5):1793–1801
Smaaland R et al (1991) DNA synthesis in human bone marrow is circadian stage dependent. Blood 77:2603–2611
Matsuo T et al (2003) Control mechanism of the circadian clock for timing of cell division in vivo. Science 302(5643):255–259. doi:10.1126/science.1086271
You S et al (2005) Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res Treat 91(1):47–60. doi:10.1007/s10549-004-6603-z
Wood PA et al (2006) Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther 5(8):2023–2033. doi:10.1158/1535-7163.MCT-06-0177
Schernhammer ES et al (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst 93(20):1563–1568
Schernhammer ES et al (2003) Night-shift work and risk of colorectal cancer in the nurses’ health study. J Natl Cancer Inst 95(11):825–828
Viswanathan AN, Hankinson SE, Schernhammer ES (2007) Night shift work and the risk of endometrial cancer. Cancer Res 67(21):10618–10622. doi:10.1158/0008-5472.CAN-07-2485
Sack RL et al (2007) Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review. Sleep 30(11):1460–1483
Filipski E et al (2002) Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 94(9):690–697
Blask DE et al (2003) Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast Cancer Res Treat 79(3):313–320. doi:10.1023/A:1024030518065
Filipski E et al (2004) Effects of chronic jet lag on tumor progression in mice. Cancer Res 64(21):7879–7885. doi:10.1158/0008-5472.CAN-04-0674
Anisimov VN (2006) Light pollution, reproductive function and cancer risk. Neuroendocrinol Lett 27(1–2):35–52
Ancoli-Israel S, Moore PJ, Jones V (2001) The relationship between fatigue and sleep in cancer patients: a review. Eur J Cancer Care (Engl) 10(4):245–255. doi:10.1046/j.1365-2354.2001.00263.x
Sephton SE et al (2000) Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 92(12):994–1000. doi:10.1093/jnci/92.12.994
Hrushesky WJ (1985) Circadian timing of cancer chemotherapy. Science 228(4695):73–75. doi:10.1126/science.3883493
Levin RD et al (2005) Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer 93(11):1202–1208. doi:10.1038/sj.bjc.6602859
Fu L et al (2002) The circadian gene Period 2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111(1):41–50. doi:10.1016/S0092-8674(02)00961-3
Fu L, Lee CC (2003) The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 3(5):350–361. doi:10.1038/nrc1072
Sjoblom T et al (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314(5797):268–274. doi:10.1126/science.1133427
Chen ST et al (2005) Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26(7):1241–1246. doi:10.1093/carcin/bgi075
Winter S et al (2007) Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia 9(10):797–800. doi:10.1593/neo.07595
Hua H et al (2007) Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther 14(9):815–818. doi:10.1038/sj.cgt.7701061
Gery S et al (2007) The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 26(57):7916–7920. doi:10.1038/sj.onc.1210585
Devroe E, Silver PA (2002) Retrovirus-delivered siRNA. BMC Biotechnol 2:15. doi:10.1186/1472-6750-2-15
Rubinson DA et al (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33(3):401–406. doi:10.1038/ng1117
Balsalobre A, Marcacci L, Schibler U (2000) Multiple signaling pathways elicit circadian gene expression in cultured Rat-1 fibroblasts. Curr Biol 10(20):1291–1294. doi:10.1016/S0960-9822(00)00758-2
Tsuchiya Y, Akashi M, Nishida E (2003) Temperature compensation and temperature resetting of circadian rhythms in mammalian cultured fibroblasts. Genes Cells 8(8):713–720. doi:10.1046/j.1365-2443.2003.00669.x
Balsalobre A, Damiola F, Schibler U (1998) A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 93(6):929–937. doi:10.1016/S0092-8674(00)81199-X
Yagita K et al (2001) Molecular mechanisms of the biologic clock in cultured fibroblasts. Science 292:278–281. doi:10.1126/science.1059542
Gery S et al (2006) The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 22(3):375–382. doi:10.1016/j.molcel.2006.03.038
Gupta S et al (2004) Inducible, reversible, and stable RNA interference in mammalian cells. Proc Natl Acad Sci USA 101(7):1927–1932. doi:10.1073/pnas.0306111101
Liu XD et al (2004) Short hairpin RNA and retroviral vector-mediated silencing of p53 in mammalian cells. Biochem Biophys Res Commun 324(4):1173–1178. doi:10.1016/j.bbrc.2004.09.190
Hao DL et al (2005) Knockdown of human p53 gene expression in 293-T cells by retroviral vector-mediated short hairpin RNA. Acta Biochim Biophys Sin (Shanghai) 37(11):779–783. doi:10.1111/j.1745-7270.2005.00107.x
Jia F, Zhang YZ, Liu CM (2006) A retrovirus-based system to stably silence hepatitis B virus genes by RNA interference. Biotechnol Lett 28(20):1679–1685. doi:10.1007/s10529-006-9138-z
Hurst CD, Tomlinson DC, Williams SV, Platt FM, Knowles MA (2008) Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumors with 6p22 amplification. Oncogene 27(19):2716–2727
Wood PA, Hrushesky WJ, Klevecz R (1998) Distinct circadian time structures characterize myeloid and erythroid progenitor and multipotential cell clonogenicity as well as marrow precursor proliferation dynamics. Exp Hematol 26(6):523–533
Nagoshi E et al (2004) Circadian gene expression in individual fibroblasts: cell-autonomous and self-sustained oscillators pass time to daughter cells. Cell 119:693–705
Yamamoto T et al (2004) Transcriptional oscillation of canonical clock genes in mouse peripheral tissues. BMC Mol Biol 5:18. doi:10.1186/1471-2199-5-18
Alvarez JD, Sehgal A (2005) The thymus is similar to the testis in its pattern of circadian clock gene expression. J Biol Rhythms 20(2):111–121. doi:10.1177/0748730404274078
Hrushesky WJ, Lannin D, Haus E (1998) Evidence for an ontogenetic basis for circadian coordination of cancer cell proliferation. J Natl Cancer Inst 90(19):1480–1484. doi:10.1093/jnci/90.19.1480
Gorbacheva VY et al (2005) Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci USA 102:3407–3412. doi:10.1073/pnas.0409897102
Sothern RB et al (1989) Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst 81(2):135–145. doi:10.1093/jnci/81.2.135
Levi F et al (2007) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 59(9–10):1015–1035. doi:10.1016/j.addr.2006.11.001
Wood PA, Hrushesky WJ (1996) Circadian rhythms and cancer chemotherapy. Crit Rev Eukaryot Gene Expr 6(4):299–343
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, X., Wood, P.A., Oh, EY. et al. Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat 117, 423–431 (2009). https://doi.org/10.1007/s10549-008-0133-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-0133-z